Rezension:
Other amount what schedule is prescription drugs Glenview, HMA\'s largest shareholder, with 14.6% of the stock, has been a strong critic of the merger. In a press statement commenting on the merger the firm said the $7.6 billion CHS proposal \"establishes an important floor value\" for HMA shareholders to evaluate. \"As the sitting board has entered into a sale agreement concurrent with management vacancy, disappointing results, and a reduced outlook, it is difficult to assess whether the value offered… represents full and fair value or the price offered by an opportunistic acquirer to a distressed seller.\"
